BAFF-based trifunctional T-cell engagers trigger robust tumor immunity against B-cell malignancies
Protein & Cell · 2025
DOI: 10.1093/procel/pwaf054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein & Cell, 2025. Verfasst von Shuhong Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemical Oncogenomics, Shenzhen Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen 518…. Hauptthemen laut MEDLINE: T-Lymphocytes, B-Cell Activating Factor, Lymphoma, B-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Medical Research Fund, National Natural Science Foundation of China, Shenzhen Fundamental Research Program (Natural Science Foundation)-Key Basic Research Project.
Abstract (Originalsprache)
Advancements in protein engineering have driven the continuous optimization of T-cell engagers (TCEs), resulting in remarkable clinical outcomes in the treatment of B-cell malignancies. Moreover, developing tri- or multispecific TCEs has emerged as a promising strategy to address the challenges of tumor heterogeneity and antigen escape. However, considerable obstacles remain, primarily in format design. In this study, we engineered BAFF-based TCEs with various formats that incorporate anti-CD3 Fab or IgG domains fused with BAFF ligands to target BAFF receptors (BAFFR, BCMA, and TACI). These constructs varied in valency and the presence or absence of long-acting elements such as Fc domains or the albumin binding domain consensus sequence (ABDCon). Although the inclusion of an Fc domain did not enhance sustained tumor eradication, variations in valency and spatial configuration profoundly influenced cytotoxicity. We identified TriBAFF/CD3/ABDCon as the optimal trifunctional construct, featuring an anti-CD3 Fab backbone with BAFF and ABDCon fused to the C-termini of the heavy and light chains. This design facilitates optimal immune synapse formation between the target cells and T cells and effectively controls tumor burdens in various B-cell malignancy models with good tolerability. Notably, TriBAFF/CD3/ABDCon outperformed conventional therapies, including blinatumomab and BAFF-based CAR-T cells, in models of heterogeneous leukemia and aggressive lymphoma. These findings underscore the potential of using natural ligands as antibody-targeting modules and provide valuable insights into the design of the next generation of multispecific TCEs, which hold promise for improving treatment outcomes in a wide range of malignancies and beyond.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Chemical Oncogenomics, Shenzhen Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen 518055, China.
- Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen 518052, China.
- Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen 518132, China.
ORCID-Profile: Yu J Cao
Förderung
- Shenzhen Medical Research Fund
- National Natural Science Foundation of China
- Shenzhen Fundamental Research Program (Natural Science Foundation)-Key Basic Research Project
- National Key Research and Development Program of China
- Shenzhen Nanshan District Health System Science and Technology Major Project
- Shenzhen Fundamental Research Program (Natural Science Foundation)—Key Basic Research Project
Zitieren
APA
Li, S., Shi, L., Guo, Q., Zhao, L., Qi, X., Liu, Z., Guo, Z., & Cao, Y. J. (2025). BAFF-based trifunctional T-cell engagers trigger robust tumor immunity against B-cell malignancies. Protein & Cell. https://doi.org/10.1093/procel/pwaf054
Vancouver
Li S, Shi L, Guo Q, Zhao L, Qi X, Liu Z, et al. BAFF-based trifunctional T-cell engagers trigger robust tumor immunity against B-cell malignancies. Protein & Cell. 2025. doi:10.1093/procel/pwaf054
BibTeX
@article{Li2025,
author = {Li, Shuhong and Shi, Licai and Guo, Qiaoru and Zhao, Lijun and Qi, Xuexiu and Liu, Zelin and Guo, Zhi and Cao, Yu J},
title = {BAFF-based trifunctional T-cell engagers trigger robust tumor immunity against B-cell malignancies},
journal = {Protein & Cell},
year = {2025},
doi = {10.1093/procel/pwaf054}
}
EUVIMED